Attached files
file | filename |
---|---|
EX-23.2 - EX-23.2 - YIELD10 BIOSCIENCE, INC. | a17-28240_8ex23d2.htm |
EX-23.1 - EX-23.1 - YIELD10 BIOSCIENCE, INC. | a17-28240_8ex23d1.htm |
EX-5.1 - EX-5.1 - YIELD10 BIOSCIENCE, INC. | a17-28240_8ex5d1.htm |
As filed with the Securities and Exchange Commission on December 18, 2017
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
YIELD10 BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
2870 |
|
04-3158289 |
(State or Other Jurisdiction of |
|
(Primary Standard Industrial |
|
(I.R.S. Employer |
19 Presidential Way
Woburn, Massachusetts 01801
(617) 583-1700
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Dr. Oliver P. Peoples
President & Chief Executive Officer
Yield10 Bioscience, Inc.
19 Presidential Way
Woburn, Massachusetts 01801
(617) 583-1700
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
Megan N. Gates, Esq. |
|
Michael Nertney, Esq. |
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the Securities Act), check the following box. o
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x File No. 333-221283
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer o |
Accelerated filer |
o |
Non-accelerated filer o (Do not check if a smaller reporting company) |
Smaller reporting company |
x | |
|
|
Emerging growth company |
o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered |
|
Proposed Maximum |
|
Amount of |
| ||
Class A Units consisting of: |
|
$ |
|
|
|
| |
(i) Shares of common stock, par value $0.01 per share |
|
|
|
|
| ||
(ii) Series A Warrants to purchase common stock |
|
|
|
|
| ||
(iii) Series B Warrants to purchase common stock |
|
|
|
|
| ||
Class B Units consisting of: |
|
$ |
|
|
|
| |
(i) Shares of Series A Preferred Stock, par value $0.01 |
|
|
|
|
| ||
(ii) Shares of common stock issuable on conversion of Series A Preferred Stock (3) |
|
|
|
|
| ||
(iii) Series A Warrants to purchase common stock |
|
|
|
|
| ||
(iv) Series B Warrants to purchase common stock |
|
|
|
|
| ||
Common Stock issuable upon exercise of Warrants |
|
$ |
|
|
|
| |
Total |
|
$ |
6,037,500.00 |
|
$ |
751.67 |
|
(1) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the Securities Act).
(2) Includes the price of additional shares of common stock and warrants to purchase shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any.
(3) No separate fee is required pursuant to Rule 457(i) under the Securities Act.
This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE
This Registration Statement is being filed with the Securities and Exchange Commission (the Commission) pursuant to Rule 462(b) under the Securities Act of 1933, as amended. This Registration Statement incorporates by reference the contents of, including all amendments and exhibits thereto and all information incorporated by reference therein, the Registration Statement on Form S-1 (Registration No. 333-221283), which was declared effective by the Commission on December 18, 2017, and is being filed solely for the purpose of registering an increase in the maximum aggregate offering price of $6,037,500. The required opinions and consents are listed on the Exhibit Index attached hereto.
EXHIBIT INDEX
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Massachusetts, on December 18, 2017.
|
YIELD 10 BIOSCIENCE, INC. | |
|
|
|
|
By: |
/s/ Oliver P. Peoples |
|
|
Oliver P. Peoples President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date | ||
|
|
|
|
| ||
/s/ Oliver P. Peoples |
|
Director, President and Chief Executive Officer |
|
December 18, 2017 | ||
Oliver P. Peoples |
|
(Principal Executive Officer) |
|
| ||
|
|
|
|
| ||
/s/ Charles B. Haaser |
|
Chief Accounting Officer |
|
December 18, 2017 | ||
Charles B. Haaser |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
| ||
|
|
|
|
| ||
By: |
* |
|
Director |
|
December 18, 2017 | |
Joseph Shaulson |
|
|
|
| ||
|
|
|
|
| ||
By: |
* |
|
Director |
|
December 18, 2017 | |
Peter N. Kellogg |
|
|
|
| ||
|
|
|
|
| ||
By: |
* |
|
Director |
|
December 18, 2017 | |
Richard Hamilton |
|
|
|
| ||
|
|
|
|
| ||
By: |
* |
|
Director |
|
December 18, 2017 | |
Anthony J. Sinskey |
|
|
|
| ||
|
|
|
|
| ||
By: |
* |
|
Director |
|
December 18, 2017 | |
Robert L. Van Nostrand |
|
|
|
| ||
|
|
|
|
| ||
|
|
|
|
| ||
* By: |
/s/ Oliver P. Peoples |
|
|
|
| |
|
Oliver P. Peoples |
|
|
|
| |
|
Attorney-in-Fact |
|
|
|
| |